<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2011-170</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-322</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACOTHERAPY</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАКОТЕРАПИЯ</subject></subj-group></article-categories><title-group><article-title>Treatment for poststroke spasticity, the use of mydocalm</article-title><trans-title-group xml:lang="ru"><trans-title>Лечение постинсультной спастичности, применение мидокалма</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Парфенов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Parfenov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="en"><p>Department of Nervous Diseases</p></bio><email xlink:type="simple">vladimirparfenov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кафедра нервных болезней Первого МГМУ им. И.М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>13</day><month>09</month><year>2011</year></pub-date><volume>3</volume><issue>3</issue><issue-title>NO3 (2011)</issue-title><fpage>65</fpage><lpage>70</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Parfenov V.A., 2011</copyright-statement><copyright-year>2011</copyright-year><copyright-holder xml:lang="ru">Парфенов В.А.</copyright-holder><copyright-holder xml:lang="en">Parfenov V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/322">https://nnp.ima-press.net/nnp/article/view/322</self-uri><abstract><p>The paper gives the data available in the literature on the treatment of spasticity in poststroke patients. Therapeutic exercises that should be started just on the first days of stroke are noted to play a leading role in the treatment of poststroke spasticity. The local administration of botulinum toxin preparations (botox, dysport, xeomin) may be effective for managing local spasticity that deteriorates motor functions. Baclofen (baklosan), tizanidine (sirdalud), and tolperisone hydrochloride (mydocalm) may be used as oral medications. The paper also presents the results of a placebo-controlled trial that has indicated that mydocalm given in a dose of 300 to 900 mg/day may be effective in treating poststroke spasticity.</p></abstract><trans-abstract xml:lang="ru"><p>Представлены данные литературы о лечении спастичности у больных, перенесших инсульт. Отмечается, что ведущую роль в лечении постинсультной спастичности играет лечебная гимнастика, которую нужно начинать уже в первые дни после развития инсульта. При локальной спастичности, вызывающей ухудшение двигательных функций, может быть эффективным локальное введение препаратов ботулинического токсина (ботокс, диспорт, ксеомин). В качестве пероральных лекарственных средств могут использоваться баклофен (баклосан), тизанидин (сирдалуд) и толперизона гидрохлорид (мидокалм). Представлены результаты плацебоконтролируемого исследования, показавшего эффективность и безопасность применения мидокалма в дозе от 300 до 900 мг/сут при лечении постинсультной спастичности.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>постинсультная спастичность</kwd><kwd>ботулинический токсин</kwd><kwd>толперизона гидрохлорид (мидокалм)</kwd></kwd-group><kwd-group xml:lang="en"><kwd>poststroke spasticity</kwd><kwd>botulinum toxin</kwd><kwd>tolperisone hydrochloride (mydocalm)</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
